Skip to main content
Premium Trial:

Request an Annual Quote

Eurobio Scientific to Commercialize CirrusDx Molecular Biology Instrument in France, North Africa

NEW YORK – French in vitro diagnostics firm Eurobio Scientific said on Monday it has reached a deal with CirrusDx to commercialize its molecular biology platform, T-COR 8, in France and in the Maghreb countries of North Africa.

Financial and other terms of the deal were not disclosed. The Maghreb countries include Algeria, Libya, Mauritania, Morocco, Tunisia, and Western Sahara.

T-COR 8 is a real-time PCR thermocycler originally developed for the US Army and offered by Tetracore Group. CirrusDx, headquartered in Rockville, Maryland, is the commercial arm of Tetracore. The instrument is highly compact and mobile and can be used for emergency or decentralized applications at the point of care, Eurobio said in a statement.

The company added that T-COR 8 is designed to run assays individually in real time and has eight independent wells, allowing for the simultaneous analyses of up to eight patient samples.

Paris-based Eurobio said it will develop a new range of proprietary products for the T-COR 8 instrument, which will complement the EurobioPlex suite of tests already available for use with Seegene's high-speed multiplex platform.

The new kits will include tests for detecting pathogens, including those for infectious diseases such as meningitis (viruses and bacterial) and viral diseases including Dengue fever. Eurobio plans to pursue CE-IVD marking for the new tests. It added that five kits have been CE-marked and plans to get such designation for 15 other tests.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.